Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Bibliographic Details
Main Authors:	Mcmurray, J, Laakso, M, Standl, E, Tognoni, G, Holman, R, Giles, T, Martinez, F, Thomas, L, Haffner, S, Califf, R
Format:	Journal article
Published:	2011

Similar Items

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
by: Bales, C, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
by: Holman, R, et al.
Published: (2010)

Effect of Valsartan on the Incidence of Diabetes REPLY
by: Holman, R, et al.
Published: (2010)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Effect of valsartan on the incidence of diabetes and cardiovascular events.
by: McMurray, J, et al.
Published: (2010)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
by: Dos Santos, M, et al.
Published: (2017)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

Fatal attraction
by: Mohtarrudin, Norhafizah
Published: (2015)

Fatalism and Savings
by: Shapiro, J
Published: (2011)

Fatal incomprehension
by: McLoughlin, K
Published: (2018)

Fatal revenant /
by: Donaldson, Stephen

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
by: Holman, R, et al.
Published: (2003)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
by: McMurray, J, et al.
Published: (2004)

Valuation of Fatal and Non-Fatal Injuries Due to Motorcycle Accidents in Malaysia
by: Mohd Yusoff, Mohd Faudzi
Published: (2006)

The Fatal competition [kasetvideo]
Published: (1977)

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
by: Stevens, R, et al.
Published: (2004)

Kasus fatal dan nyaris fatal pada induksi persalinan dengan misoprostol
by: , SUKASTYO, Haris, et al.
Published: (2002)

Kasus fatal dan nyaris fatal pada induksi persalinan dengan misoprostol
by: , SUKASTYO, Haris, et al.
Published: (2002)

Relative toxicity of analgesics commonly used for intentional self-poisoning: a study of case fatality based on fatal and non-fatal overdoses
by: Hawton, K, et al.
Published: (2019)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in Type 2 diabetes
by: Mohanlal, N, et al.
Published: (2002)

TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.
by: Kwiatkowski, D, et al.
Published: (1990)

Aneuploidy: Cancer's Fatal Flaw?
by: Williams, Bret R., et al.
Published: (2012)

Animal phylogeny: fatal attraction.
by: Telford, M, et al.
Published: (2005)

Fatal accidents in construction 1978
by: Great Britain. Factory Inspectorate
Published: (1981)

Fatal traps for helicopter pilots /
by: 200673 Whyte, Greg
Published: (2007)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
by: Bethel, A, et al.
Published: (2005)